Bergen, 2 May 2006: NorDiag ASA (NORD) posted revenues of NOK 1.9 million in the first quarter of 2006, which represents an increase of 80 percent from the first quarter of 2005 and 4 percent compared to the previous quarter. Sales volumes of Genefec(TM), the company’s product for early diagnosis of colorectal cancer, increased by 59 percent compared to the same period in 2005 and 7 percent compared to the previous quarter. Further highlights for the first quarter were the launch of Genefec(TM) in Denmark and the entry of an exclusive European agreement with Transgenomic Inc.

NorDiag ASA recorded revenues of NOK 1.9 million in the first quarter of 2006 compared to NOK 1.0 million in the same period last year. The company’s operating profit for the first quarter was NOK -5.9 million compared to NOK -1.1 million for the previous year. The company’s net loss in the first quarter was NOK -5.6 million, against NOK -1.4 million in the same period last year.

During the quarter, NorDiag launched Genefec(TM) in Denmark, which was another step forward in the international rollout of the product. The cancer test is now available in all Scandinavian countries. I the first quarter of 2006, reimbursement was accorded for use of Genefec(TM) both in Denmark and the Stockholm region of Sweden. NorDiag is investing in further expansion in Europe, with efforts directed towards the established cancer diagnostics market as well as towards commenced and planned screening programmes for colorectal cancer.

NorDiag during the quarter also entered an exclusive agreement with Transgenomic Inc. to use the patent protected WAVE system in Europe. The agreement reduces costs in the Genefec process, creates barriers to market entry, and has resulted in further collaboration with Transgenomic on process optimisation.

For further information, please contact:
Christian Horn,
CEO NorDiag ASA, +47 90163153

About NorDiag ASA
NorDiag is a biotechnology company aiming to reduce mortality and treatment costs through detection of common cancers at the early, curable phases of cancer development. Early cancer detection brings the dual benefits of better patient outcomes and reduced healthcare costs. Currently NorDiag focuses on colorectal cancer through their product Genefec, a DNA based test available and reimbursed as a clinical diagnostic test in Norway, Sweden and Denmark. NorDiag has substantial know how in the field of genetics and the extraction of human DNA from faeces. The Company`s operations are subject to patent protection, both through own applications and in-licensed rights to applicable patents. NorDiag has its offices in Bergen, Norway, and London, UK. For more information, please consult the Company`s web pages at www.nordiag.no.